Related Experiment Video

Updated: May 4, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
09:33

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling

Published on: March 20, 2018

13.4K

A-ring modified betulinic acid derivatives as potent cancer preventive agents

Hsin-Yi Hung1, Kyoko Nakagawa-Goto2, Harukuni Tokuda3

  • 1Natural Products Research Laboratories, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599-7568, USA; Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung 401, Taiwan.

Bioorganic & Medicinal Chemistry Letters
|January 14, 2014
PubMed

Insights

New betulinic acid derivatives show strong chemopreventive potential against Epstein-Barr virus activation. Compound 8 demonstrated significant inhibition, outperforming curcumin, and showed promise in mouse skin cancer models.

Area of Science:

  • Medicinal Chemistry
  • Natural Product Derivatives
  • Cancer Chemoprevention

Background:

  • Betulinic acid (BA) is a natural compound with known biological activities.
  • Chemoprevention strategies aim to prevent cancer development.
  • Epstein-Barr virus (EBV) early antigen (EBV-EA) activation is a marker for cancer research.

Purpose of the Study:

  • To design and synthesize novel 3,4-seco betulinic acid (BA) derivatives.
  • To evaluate the chemopreventive potential of these derivatives.
  • To identify potent compounds for further investigation in cancer models.

Main Methods:

  • Synthesis of ten new 3,4-seco betulinic acid derivatives.
  • In vitro assay using 12-O-tetradecanoylphorbol-13-acetate (TPA) to induce EBV-EA activation in Raji cells.
  • In vivo mouse skin carcinogenesis assay to confirm efficacy.

Main Results:

  • Compounds 7-15 exhibited enhanced chemopreventive ability in the EBV-EA activation assay.
  • Derivatives with a free C-28 carboxylic acid (7, 8, 11, 13) showed significant inhibition.
  • Compound 8 demonstrated potent inhibition, comparable to or better than curcumin.
  • Compounds 8 and 11 showed confirmed chemopreventive activity in vivo.

Conclusions:

  • Novel 3,4-seco betulinic acid derivatives possess significant chemopreventive properties.
  • The presence of a free C-28 carboxylic acid is crucial for potent activity.
  • Compound 8 is a highly promising candidate for further development in cancer chemoprevention.
Keywords:
Betulinic acidChemopreventiveEBV-EAseco A-ring

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K
Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA04:12

Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA

Published on: December 19, 2019

14.4K

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.5K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
119